206 related articles for article (PubMed ID: 32600895)
1. Extent and distribution of peritoneal disease in patients undergoing cytoreductive surgery for first platinum sensitive recurrence in ovarian cancer and its potential therapeutic implications.
Bhatt A; Bakrin N; Gertych W; Kammar P; Parikh L; Sheth S; Shaikh S; Devouassoux-Shisheboran M; Glehen O
Eur J Surg Oncol; 2020 Dec; 46(12):2276-2282. PubMed ID: 32600895
[TBL] [Abstract][Full Text] [Related]
2. Total parietal peritonectomy performed during interval cytoreductive surgery for advanced epithelial serous ovarian cancer results in a low incidence of platinum resistant recurrence- results of a prospective multi-centre study.
Bhatt A; Sinukumar S; Parikh L; Mehta S; Shaikh S; Jumle N; Kammar P
Eur J Surg Oncol; 2021 Aug; 47(8):2150-2157. PubMed ID: 33875284
[TBL] [Abstract][Full Text] [Related]
3. Distribution of residual disease in the peritoneum following neoadjuvant chemotherapy in advanced epithelial ovarian cancer and its potential therapeutic implications.
Bhatt A; Bakrin N; Kammar P; Mehta S; Sinukumar S; Parikh L; Shaikh S; Mishra S; Mallaya M; Kepenekian V; Benzerdjeb N; Glehen O
Eur J Surg Oncol; 2021 Jan; 47(1):181-187. PubMed ID: 33071172
[TBL] [Abstract][Full Text] [Related]
4. Patterns of pathological response to neoadjuvant chemotherapy and its clinical implications in patients undergoing interval cytoreductive surgery for advanced serous epithelial ovarian cancer- A study by the Indian Network for Development of Peritoneal Surface Oncology (INDEPSO).
Bhatt A; Sinukumar S; Mehta S; Damodaran D; Zaveri S; Kammar P; Mishra S; Parikh L; Ranade R; Penumadu P; Rajan F
Eur J Surg Oncol; 2019 Apr; 45(4):666-671. PubMed ID: 30661922
[TBL] [Abstract][Full Text] [Related]
5. Pattern of recurrence after interval cytoreductive surgery and HIPEC following neoadjuvant chemotherapy in primary advanced stage IIIC/IVA epithelial ovarian cancer.
Sinukumar S; Damodaran D; Ray M; Mehta S; Paul L; Bhatt A
Eur J Surg Oncol; 2021 Jun; 47(6):1427-1433. PubMed ID: 33509612
[TBL] [Abstract][Full Text] [Related]
6. Target region resection in patients undergoing cytoreductive surgery for peritoneal metastases-is it necessary in absence of visible disease?
Bhatt A; Yonemura Y; Mehta S; Benzerdjeb N; Kammar P; Parikh L; Shah MY; Shaikh S; Prabhu A; Mishra S; Sinukumar S; Kepenekian V; Bakrin N; Passot G; Glehen O
Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):582-589. PubMed ID: 31757660
[TBL] [Abstract][Full Text] [Related]
7. A comparison of outcomes following total and selective peritonectomy performed at the time of interval cytoreductive surgery for advanced serous epithelial ovarian, fallopian tube and primary peritoneal cancer - A study by INDEPSO.
Sinukumar S; Rajan F; Mehta S; Damodaran D; Zaveri S; Kammar P; Bhatt A
Eur J Surg Oncol; 2021 Jan; 47(1):75-81. PubMed ID: 30857879
[TBL] [Abstract][Full Text] [Related]
8. Specific Regions, Rather than the Entire Peritoneal Carcinosis Index, are Predictive of Complete Resection and Survival in Advanced Epithelial Ovarian Cancer.
Rosendahl M; Harter P; Bjørn SF; Høgdall C
Int J Gynecol Cancer; 2018 Feb; 28(2):316-322. PubMed ID: 29324538
[TBL] [Abstract][Full Text] [Related]
9. Salvage lymphadenectomy in recurrent ovarian cancer patients: Analysis of clinical outcome and BRCA1/2 gene mutational status.
Gallotta V; Bruno M; Conte C; Giudice MT; Davià F; Moro F; Zannoni GF; Fagotti A; De Bonis M; Capoluongo E; Scambia G; Ferrandina G
Eur J Surg Oncol; 2020 Jul; 46(7):1327-1333. PubMed ID: 32085925
[TBL] [Abstract][Full Text] [Related]
10. Pathological assessment of cytoreductive surgery specimens and its unexplored prognostic potential-a prospective multi-centric study.
Bhatt A; Yonemura Y; Benzerdjeb N; Mehta S; Mishra S; Parikh L; Kammar P; Shah MY; Prabhu A; Shaikh S; Patel MD; Isaac S; Glehen O
Eur J Surg Oncol; 2019 Dec; 45(12):2398-2404. PubMed ID: 31337527
[TBL] [Abstract][Full Text] [Related]
11. Celiac lymph node resection and porta hepatis disease resection in advanced or recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.
Martinez A; Pomel C; Mery E; Querleu D; Gladieff L; Ferron G
Gynecol Oncol; 2011 May; 121(2):258-63. PubMed ID: 21295334
[TBL] [Abstract][Full Text] [Related]
12. Functional tumour burden of peritoneal carcinomatosis derived from DWI could predict incomplete tumour debulking in advanced ovarian carcinoma.
Lee EYP; An H; Perucho JAU; Chiu KWH; Hui ES; Chu MMY; Ngan HYS
Eur Radiol; 2020 Oct; 30(10):5551-5559. PubMed ID: 32405751
[TBL] [Abstract][Full Text] [Related]
13. Prospective correlation of the radiological, surgical and pathological findings in patients undergoing cytoreductive surgery for colorectal peritoneal metastases: implications for the preoperative estimation of the peritoneal cancer index.
Bhatt A; Rousset P; Benzerdjeb N; Kammar P; Mehta S; Parikh L; Goswami G; Shaikh S; Kepenekian V; Passot G; Glehen O
Colorectal Dis; 2020 Dec; 22(12):2123-2132. PubMed ID: 32940414
[TBL] [Abstract][Full Text] [Related]
14. Total Parietal Peritonectomy Can Be Performed with Acceptable Morbidity for Patients with Advanced Ovarian Cancer After Neoadjuvant Chemotherapy: Results From a Prospective Multi-centric Study.
Bhatt A; Kammar P; Sinukumar S; Parikh L; Jumle N; Shaikh S; Mehta S
Ann Surg Oncol; 2021 Feb; 28(2):1118-1129. PubMed ID: 32748154
[TBL] [Abstract][Full Text] [Related]
15. Surgical implications of mesenteric lymph node metastasis from advanced ovarian cancer after bowel resection.
Baiocchi G; Cestari LA; Macedo MP; Oliveira RA; Fukazawa EM; Faloppa CC; Kumagai LY; Badiglian-Filho L; Menezes AN; Cunha IW; Soares FA
J Surg Oncol; 2011 Sep; 104(3):250-4. PubMed ID: 21472733
[TBL] [Abstract][Full Text] [Related]
16. [Technical essentials and safety analysis of "rolling carpet" cytoreduction surgery in stage Ⅲc epithelial ovarian cancer].
Liu H; Shi Y; Zhang GN; Yu J; Xu SQ; Wang DF; Fan Y; Song SQ; Zhou FZ
Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):521-528. PubMed ID: 32854476
[No Abstract] [Full Text] [Related]
17. A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.
Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
Am J Obstet Gynecol; 2019 Oct; 221(4):326.e1-326.e7. PubMed ID: 31082382
[TBL] [Abstract][Full Text] [Related]
18. Extent of Peritoneal Resection for Peritoneal Metastases: Looking Beyond a Complete Cytoreduction.
Bhatt A; Glehen O
Ann Surg Oncol; 2020 May; 27(5):1458-1470. PubMed ID: 31965374
[TBL] [Abstract][Full Text] [Related]
19. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer.
Manzanedo I; Pereira F; Pérez-Viejo E; Serrano Á; Hernández-García M; Martínez-Torres B; Rihuete-Caro C; Calzas J; Cueto M
Minerva Ginecol; 2017 Apr; 69(2):119-127. PubMed ID: 27415829
[TBL] [Abstract][Full Text] [Related]
20. Ovarian cancer patients with localized relapse: clinical outcome and prognostic factors.
Petrillo M; Fagotti A; Ferrandina G; Fanfani F; Costantini B; Vizzielli G; Pedone Anchora L; Nero C; Margariti PA; Scambia G
Gynecol Oncol; 2013 Oct; 131(1):36-41. PubMed ID: 23791829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
